RLAY - Relay Therapeutics, Inc.
收市後：
| 前收市價 | 11.47 |
| 開市 | 11.47 |
| 買盤 | 0.00 x 800 |
| 賣出價 | 0.00 x 800 |
| 今日波幅 | 11.14 - 12.00 |
| 52 週波幅 | 9.67 - 33.06 |
| 成交量 | |
| 平均成交量 | 1,644,180 |
| 市值 | 1.394B |
| Beta 值 (5 年，每月) | 1.30 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -2.88 |
| 業績公佈日 | 2023年8月02日 - 2023年8月07日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 28.32 |
Insider MonkeyAnalysts Are Upgrading These 10 Stocks
In this article, we will discuss the 10 stocks recently upgraded by analysts. If you want to see more such stocks on the list, you can directly visit Analysts Are Upgrading These 5 Stocks. Although the equity markets have been buoyed by the expectation of lower interest rates this year, we may likely see an increase […]
BenzingaRelay Therapeutics' Stock Price Premium Vs Peers Is Justified By Its Platform Technology, Analyst Says
Raymond James initiated coverage of Relay Therapeutics Inc (NASDAQ: RLAY) with an Outperform rating and a price target of $29 based upon the stock trading at 8x our EV/5-year forward sales estimate. The price is a premium to small-cap peers trading at 1-2x and mid-cap peers at ~3x, justified by Relay’s platform technology for identifying selective agents against validation targets in oncology and near-term potential for platform validation. The analyst expects a marked reduction in high-grade hy
InvestorPlaceGet In Now. 7 Stocks That Are Set to Soar.
While anybody can come up with stocks to buy that may rise over a period of time, predicting which ones will rise imminently represents a whole new ballgame. Allow me to be blunt here: I have zero – absolutely zero – clue as to whether the enterprises below will swing higher soon or even at all. When you introduce the time element into your speculation, the risk factor naturally multiplies. On the other hand, I’m not just going to give you a bunch of random stocks to buy. Instead, I figured that
Insider MonkeyAlphabet Inc (GOOGL) Investment Portfolio: Top 15 Companies
In this article, we discuss the top 15 companies in Alphabet Inc (GOOGL)’s investment portfolio. If you want to see more names in this portfolio, check out Alphabet Inc (GOOGL) Investment Portfolio: Top 5 Companies. GV, previously named Google Ventures, is the venture capital investment arm of Alphabet Inc. (NASDAQ:GOOG), which was founded in 2009 […]
InvestorPlace7 Unknown Biotech Stocks That Could Rocket in 2023
Investing in early-stage or unknown biotech stocks can be likened to investing in cryptocurrency projects. If the project developments are positive, returns can be multi-folds in a short time. Similarly, biotech stocks can skyrocket on the commercialization of potential blockbuster drugs. With the covid-19 pandemic, investments have surged in the biotechnology sector. As the research pipeline for various conditions deepens, the investment opportunities continue to expand. My view is underscored
BenzingaRelay Therapeutics Shares Jump After Interim Data From Bile Duct Cancer Drug Ahead Of ESMO Presentation
Relay Therapeutics Inc's (NASDAQ: RLAY) ReFocus trial for RLY-4008 was published on the European Society for Medical Oncology's (ESMO) website. The abstract has been selected for an oral presentation at the upcoming ESMO Congress 2022. Relay Therapeutics is evaluating RLY-4008, its bile duct cancer drug, for a narrow group of patients with FGFR2-altered cholangiocarcinoma. Related: Relay Therapeutics Highlights Interim Data From Bile Duct Cancer Trial. Potent efficacy was observed across all dos